Metformin improves clinical, metabolic parameters of women with PCOS

Metformin usage has beneficial effect on polycystic ovary syndrome (PCOS) women by decreasing body weight, total testosterone, BMI, androstenedione, LDL-C, 17-OHP, fasting blood glucose, and raising the chance of pregnancy, says an article published in Therapeutic Advances in Endocrinology and Metabolism by SAGE Journals.

With a frequency of up to 20%, polycystic ovarian syndrome (PCOS) is a diverse endocrine disorder that affects women of reproductive age. Menstrual abnormalities, polycystic ovarian morphology, and excess androgen are biochemical and clinical hallmarks of PCOS. The primary glucose and lipid homeostasis cell regulator AMP-activated protein kinase (AMPK), which is stimulated by metformin, decreases hepatic glucose synthesis. Inhibition of glucose in the hepatocytes is linked to AMPK activation. This research was done by Mohammed Altigani Abdalla and colleagues. to conduct a thorough assessment of the literature on the therapeutic effects of metformin on the clinical and metabolic parameters in PCOS-affected women.

For more details, check out the link given below:

Metformin Improves Clinical And Metabolic Parameters Of Women With PCOS